KR20090056171A - Anti-inflammatory composition containing geranium nepalense extract as an effective factor - Google Patents
Anti-inflammatory composition containing geranium nepalense extract as an effective factor Download PDFInfo
- Publication number
- KR20090056171A KR20090056171A KR1020070123205A KR20070123205A KR20090056171A KR 20090056171 A KR20090056171 A KR 20090056171A KR 1020070123205 A KR1020070123205 A KR 1020070123205A KR 20070123205 A KR20070123205 A KR 20070123205A KR 20090056171 A KR20090056171 A KR 20090056171A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- inflammatory
- hot water
- grass
- heterogeneous
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 81
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 34
- 244000275701 Geranium nepalense Species 0.000 title abstract description 8
- 239000000203 mixture Substances 0.000 title description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 51
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims abstract description 30
- 102000003945 NF-kappa B Human genes 0.000 claims abstract description 18
- 108010057466 NF-kappa B Proteins 0.000 claims abstract description 18
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 claims abstract description 17
- 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 claims abstract description 17
- 206010061218 Inflammation Diseases 0.000 claims abstract description 14
- 235000015140 cultured milk Nutrition 0.000 claims abstract description 12
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 244000025254 Cannabis sativa Species 0.000 claims description 28
- 239000004480 active ingredient Substances 0.000 claims description 19
- 241000195493 Cryptophyta Species 0.000 claims description 14
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 235000013376 functional food Nutrition 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 9
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 229920001542 oligosaccharide Polymers 0.000 abstract description 5
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 4
- 244000199866 Lactobacillus casei Species 0.000 abstract description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 abstract description 4
- 239000011575 calcium Substances 0.000 abstract description 4
- 229910052791 calcium Inorganic materials 0.000 abstract description 4
- 208000037976 chronic inflammation Diseases 0.000 abstract description 4
- 229940017800 lactobacillus casei Drugs 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 3
- 235000013325 dietary fiber Nutrition 0.000 abstract description 3
- 239000008103 glucose Substances 0.000 abstract description 3
- 235000013343 vitamin Nutrition 0.000 abstract description 3
- 239000011782 vitamin Substances 0.000 abstract description 3
- 229930003231 vitamin Natural products 0.000 abstract description 3
- 229940088594 vitamin Drugs 0.000 abstract description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 2
- 230000006020 chronic inflammation Effects 0.000 abstract description 2
- 235000001727 glucose Nutrition 0.000 abstract description 2
- 238000003808 methanol extraction Methods 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 abstract description 2
- 238000003809 water extraction Methods 0.000 abstract description 2
- 235000021559 Fruit Juice Concentrate Nutrition 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 description 23
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 239000000401 methanolic extract Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007902 hard capsule Substances 0.000 description 4
- -1 hydroxy fatty acids Chemical class 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019985 fermented beverage Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 229920002567 Chondroitin Polymers 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 235000021579 juice concentrates Nutrition 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000009492 vitamin B5 Nutrition 0.000 description 2
- 239000011675 vitamin B5 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- CJAOGUFAAWZWNI-UHFFFAOYSA-N 1-n,1-n,4-n,4-n-tetramethylbenzene-1,4-diamine Chemical compound CN(C)C1=CC=C(N(C)C)C=C1 CJAOGUFAAWZWNI-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229940019765 dermatin Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical group C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000021278 navy bean Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000003799 water insoluble solvent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 항염증 효능을 가지는 이질풀 추출물 및 이를 유효성분으로 함유하는 조성물에 관한 것으로서, 보다 상세하게는 본 발명은 NF-κB, 사이클로옥시게나제-2(Cyclooxygenase-2), 콘드로이티나제(chondroitinase)의 활성화 저해를 통해 항염증 효능을 가지는 이질풀 추출물 및 이를 유효성분으로 함유하는 항염증용 조성물, 발효유, 음료 및 건강기능식품에 관한 것이다.The present invention relates to a heterogeneous grass extract having an anti-inflammatory effect and a composition containing the same as an active ingredient, and more particularly, the present invention relates to NF-κB, cyclooxygenase-2, and chondroitinase ( The present invention relates to an extract of erythrocytes having anti-inflammatory efficacy through the inhibition of activation of chondroitinase and an anti-inflammatory composition, fermented milk, beverage and health functional food containing the same as an active ingredient.
염증반응은 생체의 세포나 조직에 어떠한 기질적 변화를 가져오는 침습으로 인한 손상을 수복 재생하기위한 생체방어반응과정으로서 국소의 혈관, 체액의 각종 조직세포 및 면역세포 등이 작용한다. 정상적으로 외부 침입균에 의하여 유도되는 염증반응은 생체를 보호하기 위한 방어 시스템인 반면, 비정상적으로 과도한 염증반응이 유도되면 다양한 질환들이 나타나게 되는데, 이러한 질환들을 염증질환이라 한다. 상기 염증질환은 외부 자극에 의하여 활성화된 표적세포로부터 분비되는 다양한 염증 매개물질이 염증을 증폭 및 지속시켜 인체의 생명을 위협하는 질환으로서 급성염증, 류마티스 관절염과 같은 관절 내에서의 만성염증 질환 등이 있다.Inflammatory reactions are biological defense reactions for repairing and repairing damage caused by invasion that causes certain organic changes in cells or tissues. Local blood vessels, various tissue cells of body fluids and immune cells work. Normally, the inflammatory response induced by external invading bacteria is a defense system for protecting the living body, whereas abnormally excessive inflammatory response is induced, and various diseases appear. These diseases are called inflammatory diseases. The inflammatory disease is a disease that threatens human life by amplifying and sustaining inflammation of various inflammatory mediators secreted from target cells activated by external stimuli, such as chronic inflammatory diseases in joints such as acute inflammation and rheumatoid arthritis. have.
이러한 염증질환을 유도하는 핵심적인 염증 매개물질은 프로스타글란딘류(prostaglandins), 수산화 지방산류(hydroxy fatty acids) 등이며 이들은 사이클로옥시게나제(cyclooxygenase, COX) 및 리폭시게나제(lipoxygenase)에 의하여 전구체인 아라키돈산(arachidonic acid)로부터 생성된다.The key inflammatory mediators that induce these inflammatory diseases are prostaglandins and hydroxy fatty acids, which are precursors of arachidone by cyclooxygenase (COX) and lipoxygenase. It is produced from arachidonic acid.
그런데 서구화된 식생활 및 운동부족, 환경오염 등에 의하여 현대인에게 다양한 급성 및 만성 염증 질환이 점차 증가하는 추세에 있다. 이러한 여러 가지 염증성 질환에 대한 치료로써 항생제 및 소염제가 사용되고 있으며 다양한 약제 부작용 등이 점차 문제가 되고 있다. 염증 치료를 위하여, 여러 가지 항염증 물질이 개발되었으며, 현재까지 보고된 항 염증성 물질들은 급성염증에서 손상된 조직세포, 염증에 관여하는 세포에서 활성화되는 프로스타글란딘의 생합성을 억제하는 물질들이다. 이와 같은 물질들은 급성염증에 대해서는 치료효과를 가지고 있지만 류마티스 관절염 같은 만성염증에 대해서는 1차적인 염증현상만을 완화할 뿐이며, 면역학적 치료효과는 기대할 수 없으며 또한 심혈관계를 비롯한 다양한 부작용을 가지고 있다.However, due to westernized diet, lack of exercise, and environmental pollution, various acute and chronic inflammatory diseases are gradually increasing in modern people. Antibiotics and anti-inflammatory drugs are used as treatments for various inflammatory diseases, and various side effects of drugs are gradually becoming a problem. In order to treat inflammation, various anti-inflammatory substances have been developed, and anti-inflammatory substances reported to date are substances that inhibit the biosynthesis of prostaglandins that are activated in damaged tissue cells and cells involved in inflammation in acute inflammation. These substances have a therapeutic effect on acute inflammation, but only alleviate the primary inflammation for chronic inflammation such as rheumatoid arthritis, and can not expect immunological therapeutic effects and also has various side effects including cardiovascular system.
따라서 만성염증에 효과가 탁월하며 상기와 같은 다양한 부작용과 내성 등의 문제가 없으며 안전하게 사용될 수 있는 천연물 유래 식물 추출물을 연구 하던 중 이질풀 추출물이 NF-κB, 사이클로옥시게나제-2(Cyclooxygenase-2, 이하 'COX-2'라 함), 콘드로이티나제(chondroitinase)의 활성을 저해함으로써 항염증 효능을 가짐을 발견하여 본 발명을 완성하게 되었다.Therefore, while studying the natural plant-derived plant extract that can be used safely without any problems such as the various side effects and resistance as described above, it is NF-κB, cyclooxygenase-2 (Cyclooxygenase-2, Hereinafter referred to as 'COX-2', by inhibiting the activity of chondroitinase (chondroitinase) has been found to have an anti-inflammatory effect to complete the present invention.
본 발명은 NF-κB, 사이클로옥시게나제-2(Cyclooxygenase-2), 콘드로이티나제(chondrointinase)를 저해함으로써 항염증 효능을 가지는 이질풀 추출물 및 이를 유효성분으로 함유하는 항염증용 조성물, 발효유, 음료 및 건강기능식품을 제공하는 것을 목적으로 한다.The present invention is an algae extract having anti-inflammatory effect by inhibiting NF-κB, cyclooxygenase-2, Cyclooxygenase-2, chondroitinase and anti-inflammatory composition containing the same as an active ingredient, fermented milk, An object of the present invention is to provide a beverage and a dietary supplement.
상기와 같은 목적을 달성하기 위하여, 본 발명은 NF-κB, 사이클로옥시게나제-2(Cyclooxygenase-2), 콘드로이티나제(chondrointinase)를 저해함으로써 항염증 효능을 갖는 이질풀 추출물 및 이를 유효성분으로 함유하는 항염증용 조성물, 발효유, 음료 및 건강기능식품을 제공하는 것을 특징으로 한다.In order to achieve the above object, the present invention is a heterogeneous grass extract having an anti-inflammatory effect by inhibiting NF-κB, cyclooxygenase-2, chondroitinase (chondrointinase) as an active ingredient It is characterized by providing an anti-inflammatory composition containing, fermented milk, beverages and health functional food.
이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
이질풀(Geranium nepalense sub sp. thunbergii)은 쥐손이풀과에 속하는 것으로서 한국, 일본, 타이완 등의 산과 들에서 자생하는 식물로서 그 높이는 약 50cm 정도이다. 뿌리는 곧은 뿌리가 없고 여러 개로 갈라지며, 줄기가 나와서 비스듬히 자라고 털이 퍼져 난다. 잎은 마주 달리고 3~5개로 갈라지며 너비 3~7cm이고 흔히 검은 무늬가 있다. 갈래 조각은 달걀을 거꾸로 세워놓은 모양으로서, 끝이 둔하고 얕게 3개로 갈라지며 윗부분에 불규칙한 톱니가 있다. 많은 양의 타닌과 케르세틴이 들어 있어 소염·지혈·수렴·살균 작용이 있다. 민간에서는 대장 카타르·이질·위궤양·십이지장궤양 등에 약재로 사용하고, 한방에서는 현초(玄草)라고 하며 지사제로 사용되고 있으나 아직까지 항염증 작용기전 및 항염증력은 알려진바 없다.Geranium nepalense sub sp. Thunbergii is a genus belonging to the rat handiaceae family and grows in mountains and fields of Korea, Japan and Taiwan, and its height is about 50cm. Roots do not have straight roots, split into several, stems come out, grow obliquely, and hairs spread out. Leaves are opposite each other, split into 3 ~ 5 pieces, 3 ~ 7cm wide, and often have black pattern. A forked piece is an upside down egg, with a dull, shallow tip, with irregular teeth on the top. Contains large amounts of tannins and quercetin, which is anti-inflammatory, hemostatic, astringent, and bactericidal. In civilian, it is used as a medicine for colon Qatar, dysentery, gastric ulcer, duodenal ulcer, etc. In oriental medicine, Hyuncho (현 草) is used as an antidiarrheal agent, but anti-inflammatory mechanism and anti-inflammatory activity are not known.
항염증효능을 갖는 이질풀 추출물을 효율적으로 분리하는 과정을 상세히 살펴보면 다음과 같다.Looking in detail the process of efficiently separating the heterogeneous grass extract having an anti-inflammatory effect as follows.
열수 추출의 경우, 이질풀 시료의 무게를 측정하고 시료를 분쇄한 후 10배의 증류수를 첨가하여 110℃에서 3시간 추출한 후 와트만 필터페이퍼로 2회 여과한 후 증류기를 이용하여 농축한 후 동결건조 수행하고, 동결 건조된 이질풀 시료의 무게를 측정하고 적정량의 증류수를 첨가하여 용해시킨 후 0.2㎛ 필터로 여과하여 사용 시까지 냉동고에 보관한다.In the case of hot water extraction, the weight of the heterozygous sample is measured, the sample is pulverized, 10 times distilled water is added, extracted at 110 ° C. for 3 hours, filtered twice with Whatman filter paper, concentrated using a distiller, and lyophilized. The freeze-dried alien sample is weighed, dissolved by adding an appropriate amount of distilled water, filtered through a 0.2 μm filter and stored in a freezer until use.
메탄올 추출의 경우, 이질풀 시료의 무게를 측정하고 시료를 분쇄한 후 시료 무게의 5배의 99.9% 이상의 순도를 가진 메탄올을 첨가하여 상온에서 72시간 보관하여 추출을 유도한 후 와트만 필터 페이퍼로 2회 여과한 후 증류기로 농축한 후 농축액의 2배 부피의 증류수를 첨가하고 냉동시킨 후 동결건조를 수행하고 동결 건조된 이질풀 시료의 무게를 측정하고 적정량의 DMSO를 첨가하여 이질풀 추출물의 용해 후 사용시까지 냉동고에 보관한다.In the case of methanol extraction, weigh the samples of the heterozygous grass, grind the sample, add methanol with a purity of 99.9% or more of 5 times the sample weight, and store it for 72 hours at room temperature to induce extraction. After filtration and concentration in a distiller, two times the volume of the distilled water was added to the distilled water, frozen and lyophilized. The freeze-dried samples were weighed, and an appropriate amount of DMSO was added to dissolve the extract. Store in freezer.
본 발명에 따른 항염증 효능을 갖는 이질풀 추출물을 유효성분으로 함유하는 항염증용 약학적 조성물은 경구, 경피, 피하, 정맥 또는 근육을 포함한 여러 경로를 통해 투여될 수 있다. 또한, 본 발명에 따른 항염증 효능을 갖는 이질풀추출물을 유효성분으로 함유하는 항염증용 약학적 조성물은 여러 가지 제형으로 제제화 할 수 있는데 제제화 할 경우에는 통상적으로 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제 및 계면활성제 등의 희석제 또는 부형제를 사용하여 제제화 할 수 있다. 경구투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 및 캡슐제 등이 포함되며, 이러한 고형 제제는 이질풀 추출물에 적어도 하나 이상의 부형제(예를 들면, 전분, 수크로스, 락토오스 및 젤라틴) 등이 섞여 조제된다. 또한 단순한 부형제 이외에 윤활제들도 사용될 수 있다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제 및 시럽제 등을 들 수 있는데, 흔히 사용되는 단순 희석제인 물, 액체 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제 및 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수용성 용제, 현탁제, 유제, 동결건조 제제 및 좌제가 포함된다. 비수용성용제와 현탁용제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 글리세롤 및 젤라틴 등이 사용될 수 있다.The anti-inflammatory pharmaceutical composition containing an extract of J. coli having an anti-inflammatory effect according to the present invention as an active ingredient may be administered through various routes including oral, transdermal, subcutaneous, intravenous or intramuscular. In addition, the anti-inflammatory pharmaceutical composition containing a heterogeneous grass extract having an anti-inflammatory effect according to the present invention as an active ingredient can be formulated into various formulations, when formulated, fillers, extenders, binders, wetting agents, It may be formulated using diluents or excipients such as disintegrants and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which include at least one excipient (eg, starch, sucrose, lactose and gelatin), etc. It is mixed and prepared. Lubricants may also be used in addition to simple excipients. Liquid preparations for oral administration include suspensions, solvents, emulsions, and syrups. In addition to the commonly used simple diluents, water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives, etc. May be included. Formulations for parenteral administration include sterile aqueous solutions, water-insoluble solvents, suspensions, emulsions, lyophilized formulations and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. Glycerol and gelatin may be used as the base of the suppository.
사람의 경우 통상적인 1일 투여량은 1~30 mg/kg 체중의 범위일 수 있고, 1회 또는 수회로 나누어 투여할 수 있다. 그러나 실제 투여량은 투여경로, 연령, 성별 및 체중, 건강 상태 등의 여러 관련 인자에 비추어 결정되어야 한다.For humans, a typical daily dose may range from 1 to 30 mg / kg body weight and may be administered once or in divided doses. However, the actual dosage should be determined in light of several relevant factors such as route of administration, age, sex and weight, and health status.
본 발명의 이질풀 추출물은 식용 또는 약용으로 사용되는 이질풀을 원료로 하여 독성 및 부작용이 거의 없으므로 염증 예방 또는 치료의 목적으로 장기간 복용 시에도 안심하고 사용할 수 있는 제제이다.Yield grass extract of the present invention is a preparation that can be used safely in long-term use for the purpose of preventing or treating inflammation because there is almost no toxicity and side effects as a raw material used for food or medicinal herbs.
한편, 본 발명은 상기 추출 방법에 의하여 얻어진 이질풀의 열수 추출물을 유효 성분으로 함유하는 염증 예방용 발효유, 음료 및 건강기능식품으로 사용가능하다.On the other hand, the present invention can be used as an anti-inflammatory fermented milk, beverages and health functional foods containing the hot water extract of alien grass obtained by the extraction method as an active ingredient.
상기의 이질풀의 열수 추출물을 유효 성분으로 함유하는 염증 예방용 발효유는 탈지분유로 무지유고형분 함량을 조정한 원료유에 락토바실러스 카제이 HY2782 {Lactobacillus casei HY2782; 기탁기관: 한국 종균 협회, 기탁번호 KFCC-10813, 기탁일자 1993년 12월 7일, 특허등록 제0125219호(발명의 명칭:프로파아지가 제거된 락토바실러스카제이 HY2782 및 이를 이용한 제품)}를 접종한 배양액에 과즙 농축액, 식이섬유, 포도당, 올리고당, 칼슘, 비타민, 이질풀의 열수 추출물 등을 녹여 제조된 시럽을 일정 비율로 혼합, 교반하여 균질화한 뒤 용기에 포장하여 발효유를 제조한다.The anti-inflammatory fermented milk containing the hot water extract of the algae pool as an active ingredient is lactobacillus casei HY2782 { Lactobacillus casei HY2782; Deposited Organization: Korean spawn association, Accession No. KFCC-10813, Date of Deposit, December 7, 1993, Patent Registration No. 0125219 (Name of invention: Lactobacillus skazy HY2782 and product using it) Dissolve juice concentrates, dietary fiber, glucose, oligosaccharides, calcium, vitamins, hot water extracts of heterozygous syrup in a culture solution, mix and stir in a proportion, and homogenize and prepare fermented milk.
또한 상기의 이질풀의 열수 추출물을 유효 성분으로 함유하는 염증 예방용 음료는 이질풀의 열수 추출물이 유효성분으로 포함되는 것 이외에 칼슘, 가시오가피 농축액, 액상과당, 정제수를 첨가 혼합하여 드링크용 병에 충진하여 살균한 후 실온으로 냉각하여 음료를 제조한다.In addition, the anti-inflammatory drink containing the hot water extract of the algae pool as an active ingredient, in addition to containing the hot water extract of the algae pool as an active ingredient, added to the calcium bottle, concentrated extracts, liquid fructose, purified water and mixed into the drink bottle sterilization After cooling to room temperature to prepare a beverage.
또한 상기의 이질풀의 열수 추출물을 유효 성분으로 함유하는 염증 예방용 건강기능식품은 이질풀의 열수 추출물에 영양보조성분(비타민 B1, B2, B5, B6, E 및 초산에스테르, 니코틴산 아미드), 올리고당, 50% 에탄올, 정제수를 첨가 혼합하여 과립상으로 성형하여 진공건조기에서 건조시킨 후, 12~14 메쉬(mesh)를 통과시켜 균일하게 과립을 제조하여 적당량씩 압출 성형하여 정제 또는 분말로 하거나 경질캡슐에 충전하여 경질캡슐제품으로 제조한다.In addition, the health functional food for inflammation prevention containing the hot water extract of the algae pool as an active ingredient is a nutritional supplement component (vitamin B1, B2, B5, B6, E and acetate ester, nicotinic acid amide), oligosaccharide, 50 After mixing and adding% ethanol and purified water to form granules and drying them in a vacuum dryer, the granules are uniformly prepared by passing through 12 to 14 mesh and extruded by appropriate amounts to form tablets or powders or filled into hard capsules. To produce a hard capsule product.
이상에서 살펴 본 바와 같이, 본 발명의 이질풀 추출물은 NF-κB, 사이클로옥시게나제-2(Cyclooxygenase-2), 콘드로이틴나제(chondrointinase)를 저해함으로써 항염증 효능을 가지는 작용이 탁월하여 염증성 질환의 치료 및 예방을 목적으로 하는 약학적 조성물 등으로 이용될 수 있다.As described above, the heterozygous extract of the present invention has an excellent anti-inflammatory effect by inhibiting NF-κB, cyclooxygenase-2 and chondroitinase, thereby treating inflammatory diseases. And pharmaceutical compositions for the purpose of prevention.
이하 실시예를 통하여 본 발명을 보다 상세하게 설명한다. 그러나 다음의 실시 예는 본 발명의 범위를 한정하는 것은 아니며, 본 발명의 기술적 사상의 범위 내에서 당업자에 의한 통상적인 변화가 가능하다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are not intended to limit the scope of the present invention, it is possible for the ordinary change by those skilled in the art within the scope of the technical idea of the present invention.
<실시예 1><Example 1>
이질풀 추출물의 분리 정제Separation and Purification of Algae Extract
이질풀의 열수 추출물Hydrothermal extract of algae grass
이질풀을 구입하여 수세, 풍건한 후 무게를 측정하고 길이 1cm 간격으로 분쇄하였다. 분쇄된 시료 1kg을 추출병에 넣은 후 증류수 10L를 첨가하여 110℃에서 3시간 동안 추출한 후 60 mesh로 1차 여과하고 여과지(Whatman No. 41)로 2차 여과하였다. 상기 여과지에 의한 여과액을 진공회전농축기(Eyela NE, Japan)를 사용하여 감압 농축한 후 동결 건조하여 이질풀의 열수 추출물을 제조하였다.After purchase, the water was dried and washed with air, weighed, and ground at intervals of 1 cm in length. 1 kg of the pulverized sample was placed in an extraction bottle, and 10L of distilled water was added thereto, followed by extraction at 110 ° C. for 3 hours. The filtrate by the filter paper was concentrated under reduced pressure using a vacuum rotary concentrator (Eyela NE, Japan), and then lyophilized to prepare a hot water extract of the heterogeneous grass.
이질풀의 열수 추출물의 무게를 측정하고 적정량의 증류수를 첨가하여 용해시킨 후 0.2㎛ 필터로 여과하여 사용 시까지 냉동고에 보관하였다. 상기의 건조된 시료 10㎎을 1㎖의 농도로 정제수에 녹여 항염증 효능 측정 소재로 사용하였다.Weighing hot water extract of the heterozygous pool was dissolved by adding an appropriate amount of distilled water and filtered through a 0.2㎛ filter and stored in the freezer until use. 10 mg of the dried sample was dissolved in purified water at a concentration of 1 ml and used as an anti-inflammatory efficacy measurement material.
이질풀의 메탄올 추출물Methanol extract of algae grass
이질풀을 구입하여 수세, 풍건한 후 무게를 측정하고 길이 1cm 간격으로 분쇄하였다. 분쇄된 시료 1kg을 추출병에 넣은 후 99.9% 이상의 순도를 가진 메탄올 5L를 첨가하여 상온에서 72시간 동안 추출한 후 60 mesh로 1차 여과하고 여과지(Whatman No. 41)로 2차 여과하였다. 상기 여과지에 의한 여과액을 진공회전농축기(Eyela NE, Japan)를 사용하여 감압 농축한 후 농축액의 2배 부피의 증류수를 첨가하고 냉동시킨 후 동결 건조하여 이질풀의 메탄올 추출물을 제조하였다.After purchase, the water was dried and washed with air, weighed, and ground at intervals of 1 cm in length. 1 kg of the pulverized sample was placed in an extraction bottle, 5 L of methanol having a purity of 99.9% or more was added thereto, followed by extraction for 72 hours at room temperature, followed by primary filtration with 60 mesh and secondary filtration with filter paper (Whatman No. 41). The filtrate by the filter paper was concentrated under reduced pressure using a vacuum rotary concentrator (Eyela NE, Japan), and then distilled water of 2 times the concentration of the concentrate was added, frozen, and freeze-dried to prepare a methanol extract of the coriander.
상기의 건조된 시료 10㎎을 1㎖의 농도로 DMSO에 녹여 항염증 효능 측정 소재로 사용하였다.10 mg of the dried sample was dissolved in DMSO at a concentration of 1 ml and used as an anti-inflammatory efficacy measurement material.
<실시예 2><Example 2>
이질풀 추출물을 이용한 약학적 조성물 제조Preparation of pharmaceutical composition using extract
본 발명의 이질풀 추출물을 유효 성분으로 함유하는 약학 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.It describes an example of the formulation of the pharmaceutical composition containing the extract of the haricot grass of the present invention as an active ingredient, but the present invention is not intended to limit it but only to explain in detail.
캡슐제의 제조Preparation of Capsules
이질풀 추출물 시료 100㎎, 옥수수 전분 100㎎, 유당 100㎎, 스테아린산 마그네슘 2㎎을 완전히 혼합한 후 통상의 캡슐제의 제조 방법에 따라서 경질 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.A capsule was prepared by thoroughly mixing 100 mg of Helicobula extract sample, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate, and then filling the hard gelatin capsule according to a conventional method of preparing a capsule.
산제의 제조Manufacture of powder
이질풀 추출물 시료 2g, 유당 1g을 완전히 혼합한 후 기밀포에 충진하여 통상의 산제의 제조 방법에 따라 산제를 제조하였다.After mixing 2g of algae extract extract and 1g of lactose completely, it was filled into an airtight cloth to prepare a powder according to a conventional powder preparation method.
<실시예 3><Example 3>
이질풀 열수 추출물을 이용한 발효유 제조Fermented Milk Manufacture Using Hot Water Extract
탈지분유로 무지유고형분 함량을 8~20중량%로 조정한 원료유를 72~75℃에서 15초간 살균하였다. 살균된 원료유를 37℃로 냉각시킨 후 락토바실러스 카제이 HY 2782를 106cfu/㎖의 농도로 접종하여 배양액이 pH 4~5가 될 때까지 37℃에서 배양하고 냉각시켰다. 시럽은 과즙 농축액 0.1~50중량%, 식이섬유 0.1~20중량%, 포도당 0.5~30중량%, 올리고당 0.1~15중량%, 칼슘 0.001~10 중량%, 비타민 0.0001~5중량% 및 이질풀 열수 추출물 0.01~5중량%를 녹여 제조하고 살균한 뒤 냉각하였다. 이렇게 제조된 시럽과 상기 배양액을 1:3의 부피비율로 혼합, 교반하여 균질화한 뒤 용기에 포장하여 발효유를 제조하였다. 제조된 발효유는 관능검사 결과 풍미, 물성, 전체적인 맛에서 양호한 결과를 보였다.Crude milk was sterilized for 15 seconds at 72 ~ 75 ℃ to adjust the nonfat milk solid content to 8 to 20% by weight. The sterilized crude oil was cooled to 37 ° C., and then inoculated with Lactobacillus casei HY 2782 at a concentration of 10 6 cfu / ml, and then cultured and cooled at 37 ° C. until the culture solution had a pH of 4-5. Syrup contains 0.1-50% by weight of juice concentrate, 0.1-20% by weight of dietary fiber, 0.5-30% by weight of glucose, 0.1-15% by weight of oligosaccharides, 0.001-10% by weight of calcium, 0.0001-5% by weight of vitamins and 0.01 After dissolving ~ 5% by weight, sterilized and cooled. The syrup and the culture solution thus prepared were mixed and stirred at a volume ratio of 1: 3, homogenized, and then packaged in a container to prepare fermented milk. The produced fermented milk showed good results in flavor, physical properties and overall taste.
<실시예 4><Example 4>
이질풀 열수 추출물을 이용한 음료 제조Beverage Preparation Using Lichen Extract Hot Water Extract
이질풀 열수 추출물 14중량%, 대추엑기스 1.5중량% 및 당귀농축액 7중량%에 액상과당 7.4중량%를 혼합하고 여기에 정제수를 첨가, 혼합하여 드링크용 병에 충진하여 90~95℃에서 살균한 후 실온으로 냉각하여 음료를 제조하였다.Mix 14% by weight of hot water extract of Heteroasperm extract, 1.5% by weight of jujube extract, and 7% by weight of Angelica Concentrate, and add 7.4% by weight of liquid fructose, add purified water, mix and fill into a drink bottle and sterilize at 90 ~ 95 ℃ Cooled to produce a beverage.
<실시예 5><Example 5>
이질풀 열수 추출물을 이용한 건강기능식품 제조Preparation of Health Functional Food Using Hot Water Extract
이질풀 열수 추출물 0.01~30중량%에 영양보조성분(비타민 B1, B2, B5, B6, E 및 초산에스테르, 니코틴산 아미드), 올리고당, 50% 에탄올을 상기의 이질풀 열수 추출물 100중량%에 대하여 5~10중량%가 되도록 첨가하여 고속회전 혼합기에서 혼합 하였다. 상기 혼합물에 멸균 정제수 10중량%를 첨가, 혼합하고 직경 1~2 mm의 과립상으로 성형하였다. 상기 성형된 과립은 40℃~50℃의 진공건조기에서 건조시킨 후, 12~14 메쉬(mesh)를 통과시켜 균일하게 과립을 제조하였다. 상기와 같이 제조된 과립은 적당량씩 압출 성형되어 정제 또는 분말로 되거나 경질캡슐에 충전되어 경질캡슐제품으로 제조될 수 있다.Nutritional supplements (vitamins B1, B2, B5, B6, E and acetic acid ester, nicotinic acid amide), oligosaccharides, and 50% ethanol in 0.01 to 30% by weight, It was added to the weight percent and mixed in a high speed mixer. 10% by weight of sterile purified water was added to the mixture, mixed, and molded into granules having a diameter of 1 to 2 mm. The molded granules were dried in a vacuum dryer at 40 ° C.-50 ° C., and then uniformly prepared granules were passed through 12 to 14 mesh. The granules prepared as described above may be extruded by appropriate amounts into tablets or powders or filled into hard capsules to produce hard capsule products.
<시험예 1><Test Example 1>
이질풀 메탄올 추출물의 NF-κB 저해활성 측정NF-κB Inhibitory Activity of Methanol Extract
상기 실시예 1에서 제조한 이질풀의 메탄올 추출물 시료를 이용하여 염증유발 기작에 주요인자로 역할을 가지는 NF-κB의 저해활성을 측정하고자 하였다. 이를 위하여 인간 대장세포 유래 세포주인 Caco-2 cell(ATCC HTB-37)과 NF-κB 전사조절개시인자가 연속으로 3개 존재하며 뒤에 리포터(Reporter) 유전자로 루시페라아제(luciferase) 유전자가 존재하여 NF-κB의 활성화시 루시페라아제가 발현되도록 고안된 플라스미드 벡터인 3κB를 이용하였다.The methanol extract samples of the heterozygous grass prepared in Example 1 were used to determine the inhibitory activity of NF-κB, which plays a major role in the mechanism of inflammation. For this, Caco-2 cell (ATCC HTB-37), a human colon cell-derived cell line, and three NF-κB transcriptional regulators are present in succession, followed by luciferase gene as a reporter gene. 3κB, a plasmid vector designed to express luciferase upon activation of κB was used.
시험방법으로는 T25 플라스크에 50%정도 자란 Caco-2 세포에 3κB 플라스미드 2.5㎍과 6.25㎕의 리포펙타민2000(lipofectamine 2000, Invitrogen 社)을 이용하여 트랜스펙션(transfection)을 수행하였다. 6시간 후 세포를 수거하고 96 well plate로 옮기면서 NF-κB를 활성화 시키는 5ng/㎖의 인터루킨-1β(Interleukin-1β, IL-1β)와 100㎍/㎖의 이질풀의 메탄올 추출물 시료를 동시에 처리하고 다시 16시간 후에 Bright-GloTM Luciferase Assay System (Promega 社) kit을 이용하여 루시페라아제의 반응을 유도하고 루미노미터(luminometer, Biotek 社)로 그 반응치를 측정하고 NF-κB의 저해율을 조사하였다.As a test method, transfection was performed using 2.5 μg of 3κB plasmid and 6.25 μl of lipofectamine 2000 (Invitrogen, Inc.) on Caco-2 cells grown about 50% in T25 flasks. After 6 hours, the cells were collected and transferred to a 96 well plate, simultaneously treated with 5 ng / ml of Interleukin-1β and IL-1β, which were used to activate NF-κB, and methanol extract samples of 100 μg / ml After 16 hours, the luciferase reaction was induced using a Bright-Glo ™ Luciferase Assay System (Promega) kit, and the reaction value was measured using a luminometer (Biotek, Inc.) and the inhibition rate of NF-κB was investigated.
그 결과 이질풀의 메탄올 추출물이 IL-1β의 NF-κB 활성화를 거의 기저수준으로 낮추는 105%의 NF-κB 저해활성을 보이는 것을 확인할 수 있었다.As a result, Methanol extract of Helicoptera showed 105% NF-κB inhibitory activity, which lowered the NF-κB activation of IL-1β to almost the basal level.
<시험예 2><Test Example 2>
이질풀의 열수 추출물의 농도별 NF-κB 저해활성 측정Determination of NF-κB Inhibitory Activity by Concentration of Hot Water Extract
이질풀 열수 추출물의 농도에 따른 NF-κB 저해활성을 상기 시험예 1과 같은 Caco-2 세포 및 3κB 플라스미드 벡터를 이용한 루시페라아제 리포터 분석(luciferase reporter assay)을 통해서 조사하였다. 그 결과를 도 1에 나타내었다.The NF-κB inhibitory activity according to the concentration of the heterozygous hydrothermal extract was investigated by luciferase reporter assay using Caco-2 cells and 3κB plasmid vector as in Test Example 1. The results are shown in FIG.
도 1에서 확인할 수 있는 바와 같이, 이질풀 열수 추출물의 농도가 증가할수록 NF-κB 저해활성이 증가하며 이질풀 열수 추출물의 IC50은 약 41㎍/㎖ 임을 알 수 있었다.As can be seen in Figure 1, NF-κB inhibitory activity was increased as the concentration of the heterozygous hydrothermal extract was increased, and the IC 50 of the heterozygous hydrothermal extract was about 41 µg / ml.
<시험예 3><Test Example 3>
이질풀 열수 추출물의 Of algae hot water extract In VitroIn vitro COX-2 효소 저해 활성 측정 Determination of COX-2 Enzyme Inhibitory Activity
이질풀의 열수 추출물을 이용하여 염증 반응에 중요한 역할을 하는 COX-2 효소의 활성에 미치는 영향을 조사하였다. COX-2 효소 저해활성은 흡광도를 이용하여 측정하였다. 구체적으로 최종 농도로 50nM의 COX-2를 100mM Tris-HCl 완충용액(pH 8.0)에 넣고 0.5μM의 Heme을 첨가하였다. 상기 COX-2용액과 측정하고자 하는 이질풀 열수 또는 메탄올 추출물을 농도별로 혼합하고 5분간 유지하였다. 100μM의 아라키도닉산(arachidonic acid)과 10μM의 TMPD (N,N,N',N'-tetramethyl-p-phenylenediamine)을 넣어 반응을 시작하였고 5분간 반응한 후 590nm에서 흡광도를 측정하였다. 그 결과를 도 2에 나타내었다.The hydrothermal extracts of the algae grass were used to investigate the effects of COX-2 enzymes, which play an important role in the inflammatory response. COX-2 enzyme inhibitory activity was measured using absorbance. Specifically, 50 nM of COX-2 was added to 100 mM Tris-HCl buffer solution (pH 8.0) at a final concentration, and 0.5 μM of Heme was added thereto. The COX-2 solution and heterogeneous hot water or methanol extract to be measured were mixed by concentration and maintained for 5 minutes. The reaction was started by adding 100 μM of arachidonic acid and 10 μM of TMPD ( N, N, N ', N'-tetramethyl-p-phenylenediamine). After 5 minutes, the absorbance was measured at 590 nm. The results are shown in FIG.
저해율 계산법Inhibition rate calculation
C1: 양성대조군의 흡광도 (COX-2가 있는 시험군) C1: Absorbance of the positive control (test group with COX-2)
C2: 음성대조군의 흡광도 (COX-2가 없는 시험군) C2: Absorbance of negative control group (test group without COX-2)
S1: 시료군의 흡광도 (COX-2와 시료가 모두 있는 시험군) S1: absorbance of sample group (test group with both COX-2 and sample)
S2: 시료대조군의 흡광도 (COX-2가 없고 시료가 있는 시험군) S2: Absorbance of the sample control group (test group without sample without COX-2)
도 2에서 확인할 수 있는 바와 같이, 이질풀 열수 추출물의 농도가 증가할수록 COX-2 효소 저해활성이 증가하며 이질풀 열수 추출물의 IC50은 31μg/㎖임을 알 수 있었다.As can be seen in Figure 2, the COX-2 enzyme inhibitory activity increases as the concentration of the heterozygous hydrothermal extract increases, and the IC 50 of the heterohydrothermal hydrothermal extract was 31 μg / ml.
<시험예 4><Test Example 4>
이질풀 열수 추출물의 COX-2 프로모터 저해 활성 측정Determination of COX-2 Promoter Inhibitory Activity of Hot Water Extracts
이질풀 열수 추출물의 COX-2 프로모터(Promotor)의 발현 조절에 관한 영향을 조사하였다. COX-2 프로모터 저해 활성은 인간 대장세포 유래 세포주인 Caco-2 cell(ATCC HTB-37)과 COX-2 프로모터와 리포터(Reporter) 유전자로 루시페라아제(luciferase) 유전자가 존재함으로써 COX-2의 활성시 루시페라아제가 발현되도록 고안된 플라스미드를 이용하여 측정하였다. 시험방법으로는 T25 플라스크에 50% 정도 자란 Caco-2 세포에 플라스미드 2.5㎍과 6.25㎕의 리포펙타민2000(lipofectamine 2000, Invitrogen 社)을 이용하여 트랜스펙션(transfection)을 수행하였다. 6시간 후 세포를 수거하고 96 well plate로 옮기면서 NF-κB를 활성화 시키는 5ng/㎖의 IL-1β와 100㎍/㎖의 이질풀 열수 추출물 시료를 동시에 처리하고 다시 16시간 후에 Bright-GloTM Luciferase Assay System (Promega 社) kit을 이용하여 루시페라아제의 반응을 유도하고 루미노미터(luminometer ,Biotek 社)로 그 반응치를 측정하고 COX-2 프로모터의 저해율을 조사하였다. 그 결과를 도 3에 나타내었다.The effects of the control of the expression of COX-2 promoter of Helicoptera hot-water extract were investigated. The inhibitory activity of COX-2 promoter is luciferase when COX-2 is activated by the presence of luciferase gene as Caco-2 cell (ATCC HTB-37) and COX-2 promoter and reporter gene. Was measured using a plasmid designed to be expressed. As a test method, transfection was performed using 2.5 μg of plasmid and 6.25 μl of lipofectamine 2000 (Invitrogen, Inc.) on Caco-2 cells grown about 50% in T25 flasks. After 6 hours, the cells were collected and transferred to a 96 well plate, simultaneously treated with 5ng / ml IL-1β and 100 ㎍ / ml heterozygous hydrothermal extract sample to activate NF-κB and again after 16 hours, the Bright-Glo TM Luciferase Assay System The promega kit was used to induce the luciferase reaction, and the reaction value was measured by a luminometer (Biotek) and the inhibition rate of the COX-2 promoter was investigated. The results are shown in FIG.
도 3에서 확인할 수 있는 바와 같이, 이질풀 열수 추출물의 농도가 증가할수록 COX-2 프로모터의 저해율이 증가하며 이질풀 열수 추출물의 IC50은 54 μg/㎖임을 알 수 있었다.As can be seen in Figure 3, as the concentration of the extract of hot water extract increased the inhibition rate of the COX-2 promoter and the IC 50 of the hot water extract was found to be 54 μg / ㎖.
<시험예 5><Test Example 5>
이질풀의 열수 추출물을 이용한 콘드로이티나제(Chondroitinase) 효소 저해 활성 측정Determination of Chondroitinase Enzyme Inhibitory Activity Using Hot Water Extracts
정상적인 위장관 조직의 점액질부위에는 글리코사미노글리칸(glycosaminoglycan, GAG)이 다량 존재하며, 염증성 대장염 환자의 경우 정상인에 비해 글리코사미노글리칸의 조성이 달라진다. 콘드로이틴(chondroitin)과 더마틴(dermatin)은 글리코사미노글리칸의 주요 구성 성분중의 하나이다. 따라서 콘드로이틴 분해 효소인 콘드로이티나제(chondroitnase)의 활성을 저해함으로써 대장염을 예방 혹은 완화할 수 있다.Glycosaminoglycan (GAG) is present in the mucous region of normal gastrointestinal tissues, and the composition of glycosaminoglycans is different in inflammatory colitis patients compared to normal people. Chondroitin and dermatin are one of the major constituents of glycosaminoglycans. Therefore, it is possible to prevent or alleviate colitis by inhibiting the activity of chondroitinase, a chondroitin degrading enzyme.
또한 Soll 등은 인위적으로 콘드로이틴황산을 주입함으로서 인간과 동물의 관절이 염증과 같은 외상으로부터 비롯한 이 염증 완화를 확인하였다(미국특허 제5,498,606호). 이에 이질풀 열수 추출물의 시험관 내에서 콘드로이티나제의 활성 저해 유무를 조사해 보았다.In addition, Soll et al. Confirmed the alleviation of this inflammation by artificially injecting chondroitin sulfate from joints of humans and animals from trauma such as inflammation (US Pat. No. 5,498,606). Therefore, the presence or absence of inhibitory activity of chondroitinase in vitro was investigated.
콘드로이티나제(Chondroitinase)의 활성은 흡광도를 이용하여 측정하였다. 구체적으로 25 mU/㎖ 콘드로이티나제(Sigma사)를 50mM Tris HCl 완충용액(60mM Sodium acetate, pH 8.0)에 넣고 이질풀 열수 추출물을 농도별로 첨가한 후 5분간 실온에서 유지한다. 여기에 0.3㎎/㎖ 콘드로이틴 설페이트 A(chondroitin sulfate A, Sigman사)를 첨가하고 30분간 실온에서 반응한 후 반응액을 DMB (dimethylmethylene blue)용액과 반응한 후 525nm에서 흡광도를 측정하였다. 그 결과를 도 4에 나타내었다.Chondroitinase activity was measured using absorbance. Specifically, 25 mU / mL chondroitinase (Sigma) was added to 50 mM Tris HCl buffer solution (60 mM Sodium acetate, pH 8.0), and the heterozygous hydrothermal extract was added by concentration, and maintained at room temperature for 5 minutes. 0.3 mg / mL chondroitin sulfate A (Sigman Co., Ltd.) was added thereto, followed by reaction at room temperature for 30 minutes, and then the reaction solution was reacted with a dimethylmethylene blue (DMB) solution. The absorbance was measured at 525 nm. The results are shown in FIG.
도 4에서 확인할 수 있는 바와 같이, 이질풀 열수 추출물의 농도가 증가할수록 콘드로이티나제의 활성 저해율이 증가하며 이질풀 열수 추출물의 IC50은 6㎍/㎖임을 알 수 있었다.As can be seen in Figure 4, it was found that as the concentration of the hot water extract increased, the inhibitory activity of chondroitinase increased and the IC 50 of the hot water extract was 6 µg / ml.
<시험예 6><Test Example 6>
이질풀의 열수 추출물의 세포독성 시험Cytotoxicity Test of Hot Water Extracts from Algae Grass
이질풀 열수 추출물을 처리하여 Caco-2 세포에서 세포독성 및 세포 증식(cell proliferation)에 미치는 영향을 Roche 社의 Cell Proliferation KIT I (MTT)을 이용하여 MTT assay를 수행하였으며 Promega 社의 CellTiter-Gloㄾ Luminescent Cell Viability Assay kit을 이용하여 조사하였다. 실험 방법은 각각 제조사에서 추천하는 실험법을 준수하였다. 그 결과를 도 5 및 도 6에 나타내었다.MTT assay was carried out using Roche's Cell Proliferation KIT I (MTT) to evaluate the effect of Cytophyllae hydrothermal extract on cytotoxicity and cell proliferation in Caco-2 cells. The cell viability assay kit was used for the investigation. The test methods were in compliance with the test methods recommended by each manufacturer. The results are shown in FIGS. 5 and 6.
도 5 및 도 6에서 확인할 수 있는 바와 같이, 이질풀의 열수 추출물 10 내지 200㎍/㎖의 농도를 처리하였을 때 유의적인 독성을 확인할 수 없었다. 따라서 이질풀의 열수 추출물의 세포 독성은 시험한 농도 범위 내에서는 안전한 것으로 판단되었다.As can be seen in Figures 5 and 6, when treated with a concentration of 10 to 200 ㎍ / ㎖ hot water extract of the heterogeneous grass was not able to confirm significant toxicity. Therefore, the cytotoxicity of the hot water extract of the algae grass was judged to be safe within the tested concentration range.
도 1은 이질풀의 열수 추출물의 농도별 NF-κB 저해활성을 측정한 결과를 나타낸 그래프이다.1 is a graph showing the results of measuring the NF-κB inhibitory activity according to the concentration of the hot water extract of the genus.
도 2는 이질풀의 열수 추출물의 농도별 COX-2 저해 효과를 측정한 결과를 나타낸 그래프이다.Figure 2 is a graph showing the results of measuring the COX-2 inhibitory effect of each concentration of the hot water extract of the heterogeneous grass.
도 3은 이질풀의 열수 추출물의 농도별 COX-2 프로모터 활성 저해 효과를 측정한 결과를 나타낸 그래프이다.Figure 3 is a graph showing the results of measuring the inhibitory effect of COX-2 promoter activity for each concentration of the hot water extract of the heterozygous pool.
도 4는 이질풀의 열수 추출물의 농도별 콘드로이티나제(chondroitinase) 저해 효과를 측정한 결과를 나타낸 그래프이다.Figure 4 is a graph showing the results of measuring the chondroitinase (chondroitinase) inhibitory effect of each concentration of the hot water extract of the heterozygous pool.
도 5는 이질풀의 열수 추출물의 농도별 세포독성여부를 MTT assay를 통해 측정한 결과를 나타낸 그래프이다.Figure 5 is a graph showing the results of measuring the cytotoxicity by concentration of the hydrothermal extract of the heterozygous pool by MTT assay.
도 6은 이질풀의 열수 추출물의 농도별 세포 독성 여부를 세포증식(Cell proliferation)과 생존 분석(Viability Assay)을 통해서 확인한 결과를 나타낸 그래프이다.Figure 6 is a graph showing the results confirmed by the cell proliferation (Vill proliferation) and survival analysis (Viability Assay) of the concentration of the hydrothermal extract of the heterogeneous grass.
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070123205A KR20090056171A (en) | 2007-11-30 | 2007-11-30 | Anti-inflammatory composition containing geranium nepalense extract as an effective factor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070123205A KR20090056171A (en) | 2007-11-30 | 2007-11-30 | Anti-inflammatory composition containing geranium nepalense extract as an effective factor |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20090056171A true KR20090056171A (en) | 2009-06-03 |
Family
ID=40987605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070123205A KR20090056171A (en) | 2007-11-30 | 2007-11-30 | Anti-inflammatory composition containing geranium nepalense extract as an effective factor |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20090056171A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150138478A (en) * | 2014-05-29 | 2015-12-10 | 숙명여자대학교산학협력단 | Pharmaceutical composition comprising extract of Geranium krameri FR. Et SAV for Prevention or Treatment of bone diseases |
-
2007
- 2007-11-30 KR KR1020070123205A patent/KR20090056171A/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150138478A (en) * | 2014-05-29 | 2015-12-10 | 숙명여자대학교산학협력단 | Pharmaceutical composition comprising extract of Geranium krameri FR. Et SAV for Prevention or Treatment of bone diseases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101981333B1 (en) | Lactobacillus fermentum MG4231 or MG4244 having antiobesity activity derived from human and composition comprising the same | |
JP7395622B2 (en) | Novel Ficalibacterium prausnitzii strain EB-FPDK11 and its uses | |
KR101985792B1 (en) | Lactobacillus fermentum MG4231 or MG4244 having antiobesity activity derived from human and composition comprising the same | |
KR101930483B1 (en) | Smilax china leaf fermented with Aspergillus species and Extract of the same | |
KR101026528B1 (en) | Compositions for prevention and treatment of inflammatory diseases containing the extracts of seaweeds as an active ingredient | |
KR102182724B1 (en) | Antiinflammatory composition comprising Locusta migratoria extract | |
KR101770036B1 (en) | Composition comprising Schizandrae Fructus extract asan effective component for preventing and treatingarthritis | |
KR102149185B1 (en) | Enterococcus lactis Wikim0107 strain controlling immune function and ameliorating inflammatory bowel disease and use thereof | |
KR102158667B1 (en) | Pediococcus inopinatus WiKim0108 strain controlling immune function and ameliorating inflammatory bowel disease and use thereof | |
KR102169795B1 (en) | Novel Faecalibacterium prausnitzii EB-FPDK9 and Use Thereof | |
KR20090056171A (en) | Anti-inflammatory composition containing geranium nepalense extract as an effective factor | |
KR102210092B1 (en) | Lactobacillus reuteri MG505 having anticariogenic activities and composition comprising the same | |
KR20180075763A (en) | Composition comprising the ethanol extract of Portulacea oleracea for preventing and treating of Alcoholic liver damage | |
KR102123030B1 (en) | A composition for improving diabetes or for use of antioxidant comprising yeast extract and a method for preparing the yeast extract | |
KR101385191B1 (en) | Use of Cichorium intybus extracts for preventing, treating improving muscular atrophy | |
KR100493708B1 (en) | A composition with enhanced immunomodulation and anti-cancer activity | |
US8367060B2 (en) | Pharmaceutical composition containing arazyme for the prevention of liver dysfunction | |
KR20090056167A (en) | Anti-inflammatory composition containing rubus coreanum extract as an effective factor | |
KR20210147247A (en) | A composition for immune enhancement comprising narrow-leaf erecta fig extract mixture | |
KR20160090662A (en) | Composition for prevention or treatment of retinal diseases comprising small black soybean extract | |
KR102506366B1 (en) | Lactobacillus plantarum KU15120 strain or its use | |
KR100836711B1 (en) | Pharmaceutical composition containing arazyme for the prevention of liver dysfunction | |
KR20110138732A (en) | Composition comprising extracts of cedrela sinensis for anti-inflammatory activity | |
KR20090056170A (en) | Anti-inflammatory composition containing geranium koreanum extract as an effective factor | |
KR101376629B1 (en) | New Lactobacillus arizonensis BCNU 9200 and probiotics composition comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20091116 Effective date: 20100226 |